HCPCS Level II code J0218 denotes the injectable biologic olipudase alfa, billed per 1 mg unit. This code is used for therapeutic enzyme replacement administered in clinical infusion or outpatient settings and is significant nationally due to the high-cost nature and specialized administration requirements of enzyme replacement therapies. Payers nationally manage coverage and utilization of such biologics through medical benefit pathways.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for olipudase alfa, payer coverage landscape, and operational benchmarks relevant to billing and claims processing. The publication summarizes how J0218 is applied in practice, typical sites of service, and the implications for medical billing workflows.

The content covers billing benchmarks, coding considerations, and relevant policy updates that affect reimbursement and prior authorization processes for high-cost infused biologics. Clinical context explains the role of olipudase alfa as enzyme replacement therapy and typical administration settings. Data not provided in the input (such as associated ICD-10 codes, taxonomies, and related codes) is noted as unavailable where applicable.